| |
New Gilead HCV Drug GS-9190
|
| |
| |
GS-9190 is a new HCV drug in develoment by Gilead. Here is a link to earlier data presented for this drug followed by a link to the description of the phase II study that started previously.
Antiviral, pharmacokinetic and safety data for GS-9190, a non ... - [ Diese Seite ubersetzen ]
Bavisotto L, Wang C, Jacobson I, Marcellin P, Zeuzem S, Lawitz S, Lunde NM, Sereni P, O'Brien C, Oldach D, Rhodes G and the GS-9190 Study Team ...
www.natap.org/2007/AASLD/AASLD_39.htm
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of ... - [ Diese Seite ubersetzen ]
GS-9190 plasma concentrations [ Time Frame: Through Week 48 ] [ Designated as ...Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks ...
clinicaltrials.gov/ct2/show/NCT00743795
|
|
| |
| |
|
|
|
